Drug Type Monoclonal antibody |
Synonyms 德莫奇单抗, GSK-294, GSK-3511294 + [2] |
Target |
Mechanism IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D12169 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypereosinophilic Syndrome | Phase 3 | US | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | CN | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | JP | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | AR | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | AU | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | BE | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | BR | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | CZ | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | DK | 06 Sep 2022 | |
Hypereosinophilic Syndrome | Phase 3 | DE | 06 Sep 2022 |
Phase 3 | 380 | stxeulgtpl(rydrsdujcr) = statistically significant and clinically meaningful reductions in exacerbations over 52 weeks vs. placebo. gipwtgznhw (hlamsoluai ) Met | Positive | 21 May 2024 | |||
Phase 3 | 375 | khmxovppbl(tsmcwagmol) = statistically significant and clinically meaningful reductions in exacerbations over 52 weeks vs. placebo. ktuqlugczd (qsnmhnmruc ) Met | Positive | 21 May 2024 | |||
Phase 1 | 48 | gsiugmoasc(uqhmrpvjah) = no Serious Adverse Event wubyiidcqj (tarhysocgx ) View more | Positive | 22 Jul 2021 | |||
Placebo | |||||||
Phase 1 | 50 | placebo+GSK3511294 (Placebo) | pfhbcggmue(varkxkknnv) = seffjdzypr yxwmnnmpra (kzgqpjuorg, zbysstaezs - xvvthgkhrk) View more | - | 01 Mar 2021 | ||
(GSK3511294 2mg) | pfhbcggmue(varkxkknnv) = gzxjknmavr yxwmnnmpra (kzgqpjuorg, naantzbwpa - cyoupiucro) View more |